Which has preferable valuation and earnings, BRKR or TECH?

Bio-Techne has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bruker $3.44B 2.59 -$8.60M -$0.70 N/A Bio-Techne $1.22B 9.35 $181.86M $1.15 62.98

Is BRKR or TECH more profitable?

Bio-Techne has a net margin of 14.97% compared to Bruker's net margin of -2.35%. Bio-Techne's return on equity of 13.23% beat Bruker's return on equity. Company Net Margins Return on Equity Return on Assets Bruker -2.35% 12.47% 4.91% Bio-Techne 14.97% 13.23% 10.61%

Does the media favor BRKR or TECH?

In the previous week, Bio-Techne had 5 more articles in the media than Bruker. MarketBeat recorded 12 mentions for Bio-Techne and 7 mentions for Bruker. Bio-Techne's average media sentiment score of 1.38 beat Bruker's score of 0.69 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bruker 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor BRKR or A?

In the previous week, Agilent Technologies had 13 more articles in the media than Bruker. MarketBeat recorded 20 mentions for Agilent Technologies and 7 mentions for Bruker. Agilent Technologies' average media sentiment score of 0.90 beat Bruker's score of 0.69 indicating that Agilent Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bruker 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agilent Technologies 10 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, BRKR or IQV?

IQVIA has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bruker $3.44B 2.59 -$8.60M -$0.70 N/A IQVIA $16.31B 2.70 $1.36B $8.06 33.17

Is BRKR or IQV more profitable?

IQVIA has a net margin of 8.10% compared to Bruker's net margin of -2.35%. IQVIA's return on equity of 30.25% beat Bruker's return on equity. Company Net Margins Return on Equity Return on Assets Bruker -2.35% 12.47% 4.91% IQVIA 8.10% 30.25% 6.54%

Does the media prefer BRKR or IQV?

In the previous week, IQVIA had 15 more articles in the media than Bruker. MarketBeat recorded 22 mentions for IQVIA and 7 mentions for Bruker. IQVIA's average media sentiment score of 1.23 beat Bruker's score of 0.69 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bruker 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IQVIA 19 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MTD or BRKR?

In the previous week, Mettler-Toledo International had 19 more articles in the media than Bruker. MarketBeat recorded 26 mentions for Mettler-Toledo International and 7 mentions for Bruker. Mettler-Toledo International's average media sentiment score of 1.14 beat Bruker's score of 0.69 indicating that Mettler-Toledo International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mettler-Toledo International 16 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bruker 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, RVTY or BRKR?

Revvity has higher earnings, but lower revenue than Bruker. Bruker is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.91B 4.99 $241.20M $2.10 62.02 Bruker $3.44B 2.59 -$8.60M -$0.70 N/A

Is RVTY or BRKR more profitable?

Revvity has a net margin of 8.16% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Revvity's return on equity. Company Net Margins Return on Equity Return on Assets Revvity 8.16% 8.34% 5.01% Bruker -2.35% 12.47% 4.91%

Does the media refer more to RVTY or BRKR?

In the previous week, Revvity had 9 more articles in the media than Bruker. MarketBeat recorded 16 mentions for Revvity and 7 mentions for Bruker. Revvity's average media sentiment score of 0.97 beat Bruker's score of 0.69 indicating that Revvity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bruker 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bruker (BRKR) Competitors

$58.50 -0.91 (-1.53%)

As of 09/4/2026 04:00 PM Eastern

Compare

BRKR vs. TECH, A, IQV, MTD, and RVTY

Should you buy Bruker stock or one of its competitors? Bruker's main competitors and comparable companies include Bio-Techne (TECH), Agilent Technologies (A), IQVIA (IQV), Mettler-Toledo International (MTD), and Revvity (RVTY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Bruker compare to Bio-Techne?

Bruker (NASDAQ:BRKR) and Bio-Techne (NASDAQ:TECH) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Bruker currently has a consensus price target of $56.64, suggesting a potential downside of 3.17%. Bio-Techne has a consensus price target of $68.92, suggesting a potential downside of 4.84%. Given Bruker's stronger consensus rating and higher possible upside, analysts clearly believe Bruker is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.43
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12

Bio-Techne has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.44B	2.59	-$8.60M	-$0.70	N/A
Bio-Techne	$1.22B	9.35	$181.86M	$1.15	62.98

Bruker has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

In the previous week, Bio-Techne had 5 more articles in the media than Bruker. MarketBeat recorded 12 mentions for Bio-Techne and 7 mentions for Bruker. Bio-Techne's average media sentiment score of 1.38 beat Bruker's score of 0.69 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bruker	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Bruker pays out -28.6% of its earnings in the form of a dividend. Bio-Techne pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

79.5% of Bruker shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 27.2% of Bruker shares are held by company insiders. Comparatively, 1.3% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bio-Techne has a net margin of 14.97% compared to Bruker's net margin of -2.35%. Bio-Techne's return on equity of 13.23% beat Bruker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	-2.35%	12.47%	4.91%
Bio-Techne	14.97%	13.23%	10.61%

Summary

Bio-Techne beats Bruker on 12 of the 19 factors compared between the two stocks.

How does Bruker compare to Agilent Technologies?

Bruker (NASDAQ:BRKR) and Agilent Technologies (NYSE:A) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Agilent Technologies has a net margin of 19.53% compared to Bruker's net margin of -2.35%. Agilent Technologies' return on equity of 24.45% beat Bruker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	-2.35%	12.47%	4.91%
Agilent Technologies	19.53%	24.45%	13.09%

Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.7%. Bruker pays out -28.6% of its earnings in the form of a dividend. Agilent Technologies pays out 20.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

79.5% of Bruker shares are held by institutional investors. 27.2% of Bruker shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bruker has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Agilent Technologies has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.44B	2.59	-$8.60M	-$0.70	N/A
Agilent Technologies	$6.95B	6.11	$1.30B	$5.08	29.65

In the previous week, Agilent Technologies had 13 more articles in the media than Bruker. MarketBeat recorded 20 mentions for Agilent Technologies and 7 mentions for Bruker. Agilent Technologies' average media sentiment score of 0.90 beat Bruker's score of 0.69 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bruker	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	10 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bruker presently has a consensus target price of $56.64, indicating a potential downside of 3.17%. Agilent Technologies has a consensus target price of $170.33, indicating a potential upside of 13.10%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Agilent Technologies is more favorable than Bruker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.43
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Agilent Technologies beats Bruker on 15 of the 19 factors compared between the two stocks.

How does Bruker compare to IQVIA?

Bruker (NASDAQ:BRKR) and IQVIA (NYSE:IQV) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Bruker has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

IQVIA has a net margin of 8.10% compared to Bruker's net margin of -2.35%. IQVIA's return on equity of 30.25% beat Bruker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	-2.35%	12.47%	4.91%
IQVIA	8.10%	30.25%	6.54%

IQVIA has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.44B	2.59	-$8.60M	-$0.70	N/A
IQVIA	$16.31B	2.70	$1.36B	$8.06	33.17

In the previous week, IQVIA had 15 more articles in the media than Bruker. MarketBeat recorded 22 mentions for IQVIA and 7 mentions for Bruker. IQVIA's average media sentiment score of 1.23 beat Bruker's score of 0.69 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bruker	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	19 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.5% of Bruker shares are held by institutional investors. Comparatively, 89.6% of IQVIA shares are held by institutional investors. 27.2% of Bruker shares are held by company insiders. Comparatively, 1.7% of IQVIA shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bruker presently has a consensus target price of $56.64, suggesting a potential downside of 3.17%. IQVIA has a consensus target price of $243.63, suggesting a potential downside of 8.87%. Given Bruker's higher probable upside, analysts clearly believe Bruker is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.43
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

IQVIA beats Bruker on 13 of the 16 factors compared between the two stocks.

How does Bruker compare to Mettler-Toledo International?

Mettler-Toledo International (NYSE:MTD) and Bruker (NASDAQ:BRKR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, Mettler-Toledo International had 19 more articles in the media than Bruker. MarketBeat recorded 26 mentions for Mettler-Toledo International and 7 mentions for Bruker. Mettler-Toledo International's average media sentiment score of 1.14 beat Bruker's score of 0.69 indicating that Mettler-Toledo International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mettler-Toledo International	16 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bruker	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mettler-Toledo International presently has a consensus price target of $1,445.31, suggesting a potential upside of 7.47%. Bruker has a consensus price target of $56.64, suggesting a potential downside of 3.17%. Given Mettler-Toledo International's higher probable upside, research analysts clearly believe Mettler-Toledo International is more favorable than Bruker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mettler-Toledo International	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33
Bruker	2 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.43

95.1% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 79.5% of Bruker shares are owned by institutional investors. 0.7% of Mettler-Toledo International shares are owned by company insiders. Comparatively, 27.2% of Bruker shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Mettler-Toledo International has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Bruker has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Mettler-Toledo International has a net margin of 21.91% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mettler-Toledo International	21.91%	-1,212.14%	25.11%
Bruker	-2.35%	12.47%	4.91%

Mettler-Toledo International has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mettler-Toledo International	$4.13B	6.52	$869.19M	$44.43	30.27
Bruker	$3.44B	2.59	-$8.60M	-$0.70	N/A

Summary

Mettler-Toledo International beats Bruker on 11 of the 16 factors compared between the two stocks.

How does Bruker compare to Revvity?

Revvity (NYSE:RVTY) and Bruker (NASDAQ:BRKR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, Revvity had 9 more articles in the media than Bruker. MarketBeat recorded 16 mentions for Revvity and 7 mentions for Bruker. Revvity's average media sentiment score of 0.97 beat Bruker's score of 0.69 indicating that Revvity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bruker	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has higher earnings, but lower revenue than Bruker. Bruker is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.91B	4.99	$241.20M	$2.10	62.02
Bruker	$3.44B	2.59	-$8.60M	-$0.70	N/A

Revvity currently has a consensus target price of $114.77, suggesting a potential downside of 11.88%. Bruker has a consensus target price of $56.64, suggesting a potential downside of 3.17%. Given Bruker's stronger consensus rating and higher possible upside, analysts clearly believe Bruker is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	13 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.24
Bruker	2 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.43

Revvity has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Bruker has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

86.7% of Revvity shares are owned by institutional investors. Comparatively, 79.5% of Bruker shares are owned by institutional investors. 0.9% of Revvity shares are owned by company insiders. Comparatively, 27.2% of Bruker shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Revvity pays out 13.3% of its earnings in the form of a dividend. Bruker pays out -28.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bruker is clearly the better dividend stock, given its higher yield and lower payout ratio.

Revvity has a net margin of 8.16% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Bruker	-2.35%	12.47%	4.91%

Summary

Bruker beats Revvity on 10 of the 19 factors compared between the two stocks.

Get Bruker News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRKR vs. The Competition

Export

Metric	Bruker	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.91B	$9.94B	$7.25B	$12.91B
Dividend Yield	0.34%	1.46%	2.53%	9.14%
P/E Ratio	-83.57	65.01	274.10	25.45
Price / Sales	2.59	111.91	638.20	106.29
Price / Cash	17.33	26.85	77.08	52.44
Price / Book	3.71	35.98	12.85	6.17
Net Income	-$8.60M	$56.67B	$3.49B	$350.08M
7 Day Performance	2.49%	-0.83%	1.04%	-0.14%
1 Month Performance	14.10%	4.01%	5.39%	0.94%
1 Year Performance	89.75%	24.29%	24.18%	14.02%

Bruker Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRKR Bruker	2.6654 of 5 stars	$58.50 -1.5%	$56.64 -3.2%	+89.8%	$8.91B	$3.44B	N/A	11,085	Positive News Analyst Downgrade
TECH Bio-Techne	3.4544 of 5 stars	$72.39 +0.1%	$68.92 -4.8%	+33.1%	$11.34B	$1.22B	62.95	3,100	Positive News
A Agilent Technologies	4.8335 of 5 stars	$153.37 -3.5%	$160.24 +4.5%	+17.0%	$44.91B	$6.95B	30.80	18,100	Options Volume High Trading Volume
IQV IQVIA	3.665 of 5 stars	$260.30 +0.2%	$241.88 -7.1%	+42.4%	$42.77B	$16.31B	32.30	93,000	Positive News Insider Trade
MTD Mettler-Toledo International	3.9329 of 5 stars	$1,399.02 +0.3%	$1,461.27 +4.4%	+3.1%	$27.96B	$4.03B	31.49	18,100	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRKR) was last updated on 9/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bruker (BRKR) Competitors